Investigating hormone signaling and protein synthesis in advanced prostate cancer
Hormone signaling and translation control in advanced prostate cancer
This study is looking at how certain hormones and proteins affect advanced prostate cancer, especially a tough type called androgen receptor-low castration resistant prostate cancer, to find new ways to help treat patients better.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11007160 on NIH RePORTER |
What this research studies
This research focuses on understanding how hormone signaling and the control of protein synthesis contribute to advanced prostate cancer, particularly a lethal form known as androgen receptor-low castration resistant prostate cancer (CRPC). The researchers have developed new models to study this aggressive cancer type and are exploring the mechanisms that drive its growth. By examining how specific mRNA networks are translated in cancer cells, they aim to uncover new therapeutic targets that could improve treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are American men diagnosed with advanced prostate cancer, particularly those with androgen receptor-low CRPC.
Not a fit: Patients with early-stage prostate cancer or those who do not have androgen receptor-low CRPC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that specifically target the mechanisms driving aggressive prostate cancer.
How similar studies have performed: Previous research has shown promise in targeting hormone signaling pathways in prostate cancer, suggesting that this approach may yield significant advancements.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Hsieh, Andrew Caleb — Fred Hutchinson Cancer Center
- Study coordinator: Hsieh, Andrew Caleb
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.